iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)

Naval Military Medical University

Status

Enrolling

Conditions

Cancer

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT05495685

CHEC2022-030

Details and patient eligibility

About

DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. The sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.

Enrollment

450 estimated patients

Sex

All

Ages

40 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for Cancer Arm Participants:

Able to provide a written informed consent.
Able to provide sufficient and qualified blood samples for study tests.
No prior or undergoing cancer treatment (local or systematic) with either of the following:
A. Pathologically confirmed cancer diagnosis within 42 days prior to the study blood draw.
B. High suspicious for cancer diagnosis by radiological or other routine clinical assessments, with confirmed cancer diagnosis through biopsy or surgical resection within 42 days after study blood draw.

Exclusion Criteria for Cancer Arm Participants:

Insufficient qualified blood sample for study test.
During pregnancy or lactation.
Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
Recipient of blood transfusion within 30 days prior to study blood draw.
With other known malignant tumors or multiple primary tumors.

Inclusion Criteria for Benign Disease Arm Participants:

Able to provide a written informed consent.
Able to provide sufficient and qualified blood samples for study tests.
Have either of the following:
A. Pathological confirmed diagnosis of benign diseases within 90 days prior to the study blood draw, with no prior treatment such as surgical resection.
B. High suspicious for benign diseases diagnosis by radiological or other routine clinical assessments, with confirmed benign diseases diagnosis within 42 days after study blood draw.

Exclusion Criteria for Benign Disease Arm Participants:

Insufficient qualified blood sample for study test.
During pregnancy or lactation.
Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.
Recipient of blood transfusion within 30 days prior to study blood draw.
Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer